Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia

Hematology

Volumn 10, Issue 4, 2005, Pages 321-326

  Jacobs, Peter ^a,b,c   Wood, Lucille ^a  

^a Department of Haematology and Bone Marrow Transplantation Unit   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukaemia; Cell cycle; Cytosine; Sensitivity index

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CELL AGGREGATION; CELL CYCLE; CELL GROWTH; CELL KILLING; CELL STIMULATION; CELL SURVIVAL; CLINICAL ARTICLE; CLONOGENESIS; COLONY FORMING CELL; COLONY FORMING UNIT GM; CONTROLLED STUDY; DENSITY GRADIENT; DRUG ACTIVITY; DRUG EXPOSURE; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; REMISSION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELOID PROGENITOR CELLS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS;

EID: 29144442895     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330500141622     Document Type: Article

References (41)

1. Raza A, Maheshwari Y, Ucar K, Mayers G, Preisler HD. Proliferative characteristics of acute nonlymphocytic leukemia in vivo. Acta Haematol 1987;77:140-145.
2. Raza A, Preisler HD, Day R, Yasin Z, White M, Lykins J, et al. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: A leukemia intergroup study. Blood 1990;76:2191-2197.
3. Preisler HD, Gopal V, Banavali SD, Finke D, Bokari SAJ. Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents. Cancer Res 1992;52:4090-4095.
4. Uhlman DL, Bloomfield CD, Hurd DD, Peterson BA. Prognostic factors at relapse for adults with acute myeloid leukemia. Am J Hematol 1990;33:110-116.
5. Minden M, Imrie K, Keating A. Acute leukemia in adults. Curr Opin Hematol 1996;3:259-265.
6. Bernell P, Arvidsson I, Jacobsson B, Hast R. Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukaemia. Br J Haematol 1996;95:666-672.
7. Champlin R, Gale RP. Acute myelogenous leukemia: Recent advances in therapy? Blood 1987;69:1551-1562.
8. Delwel R, van Gurp R, Bot F, Touw I, Löwenberg B. Phenotyping of acute myelocytic leukemia (AML) progenitors: An approach for tracing minimal numbers of AML cells among normal bone marrow. Leukemia 1988;2:814-819.
9. Bregni M, Siena S, Neri A, Bassan R, Barbui T, Delia D, et al. Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. J Clin Oncol 1989;7:338-343.
10. Zehnbauer BA, Pardoll DM, Burke PJ, Graham ML, Vogelstein B. Immunoglobulin gene rearrangements in remission bone marrow specimens from patients with acute lymphoblastic leukemia. Blood 1986;67:835-838.
11. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746-1751.
12. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465-2470.
13. Gerhartz HH, Schmetzer H. Detection of minimal residual disease in acute myeloid leukemia. Leukemia 1990;4:508-516.
14. Preisler HD, Bonavali SD, Yin M, Venu G, Li YQ, Gaskins F, et al. Parallel studies of clonogenic leukaemic cells and the leukaemia cell population as a whole in acute myelogenous leukaemia. Eur J Cancer 1994;30A:1511-1516.
15. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD, Jones RJ. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991;78:1125-1131.
16. Gore SD, Burke PJ, Weng LJ. Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia. Leuk Lymphoma 1998;29:339-350.
17. Kolesnikova AI, Pavlov W, Konoplyannikov AG, Lepekhina LA, Kalsina SS, Danilova MA, et al. Agar cultures of human clonogenic hemopoietic precursor cells for early diagnosis of some myeloproliferative diseases. Bull Exp Biol 2002;134:181-186.
18. Dow LW, Mirro J, Dahl GV, Kalwinsky DK, Hancock ML, Nash MB, Roberson PK. Comparison of two clonogenic assays for determining cell growth patterns in childhood acute myeloid leukemia: Relationship to clinical findings and prognosis. Leuk Res 1987;11:565-573.
19. Praloran V, Dobo I, Garand R, Klausman M, Naud MF, Milpied N, Harousseau JL. Collagen gel cultures for detection of spared hematopoietic progenitors in Asta Z 7557 purged human marrows. Leukemia 1990;4:282-286.
20. Maurer HR, Henry R. Colony growth of mouse bone marrow cells in agar contained in glass capillaries. Blut 1976;33:11-22.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group. Br J Haematol 1976;33:451-458.
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British cooperative group. Ann Intern Med 1985;103:620-625.
23. Iscove NN, Senn JS, Till JE, McCulloch EA. Colony formation by normal and leukemic human marrow cells in culture: Effect of conditioned medium from human leukocytes. Blood 1971;37:1-5.
24. Buick RN, Till JE, McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukaemia. Lancet 1977;1:862-863.
25. Winkelstein A, Simon PL, Myers PA, Weaver LD. Comparisons of 12-tetradecanoylphorbol-13-acetate (TPA) and PHA as mitogens in the T-lymphocyte colony assay. Exp Hematol 1986;14:1023-1028.
26. Yang LY, Drewinko B. Cytotoxic efficacy of reconstituted and stored antitumor agents. Cancer Res 1985;45:1511-1515.
27. Bosanquet AG. Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumour agents. Cancer Chemother Pharmacol 1989;23:197-207.
28. Dow LW, Dahl GV, Kalwinsky DK, Mirro J, Nash MB, Roberson PK. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia. Blood 1986;68:400-405.
29. Cavazzana M, Calvo F, Facchin P, Barreau P, Geny B, Dal Cortivo L, Dresch C. Use of liquid culture and cell cycle analysis to compare drug damage following in vitro treatment of normal human bone marrow cells with adriamycin, arabinosyl-cytosine, and etoposide. Exp Hematol 1988;16:876-883.
30. Park CH, Wiernik PH, Morrison FS, Amare M, Van Sloten K, Maloney TR. Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs. Cancer Res 1983;43:2346-2349.
31. Marie JP, Zittoun R, Thevenin D, Mathieu M, Viguie F. In vitro culture of clonogenic leukaemic cells in acute myeloid leukaemia: Growth pattern and drug sensitivity. Br J Haematol 1983;55:427-437.
32. Bruserud Ø, Frostad S, Foss B. In vitro culture of acute myelogenous leukemia blasts: A comparison of four different culture media. J Hematother 1999;8:63-73.
33. Öhler L, Berer A, Aletaha D, Kabrna E, Heinze G, Streubel B, et al. Cytogenetic risk groups in acute myeloblastic leukaemia differs greatly in their semi-solid colony growth. Br J Haematol 2001;113:120-125.
34. Curtis DJ, Metcalf D, Alexander B, Begley CG. Leukemic cells from murine myeloid leukemia display an intrinsic ability for autonomous proliferation. Exp Hematol 2000;28:36-45.
35. Curtis JE, Minkin S, Minen MD, McCulloch EA. A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: Preclinical cell culture studies. Br J Haematol 1996;95:354-363.
36. Curtis JE, Minden MD, Minkin S, McCulloch EA. Sensitivities of AML blast stem cells to idarubicin and daunorubicin: A comparison with normal hematopoietic progenitors. Leukemia 1995;9:396-404.
37. McCulloch EA, Curtis JE, Messner HA, Senn JS, Germanson TP. The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia (AML). Blood 1982;59:601-608.
38. Brown CH, Carbone PP. In vitro growth of normal and leukemic human bone marrow. J Natl Cancer Inst 1971;46:989-1000.
39. Malmberg M, Slocum HK, Rustum YM. A model for mimicking the pharmacokinetics of chemotherapy drugs for evaluation of drug effects in a soft agar colony formation assay system. Sel Cancer Ther 1991;7:159-164.
40. van der Lely N, de Witte T, Wessels J, Raymakers R, Muus P, Preijers F. In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: Factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Ann Hematol 1994;68:225-232.
41. Minderman H, Linssen P, van der Lely N, Wessels J, Boezeman J, de Witte T, Hannen C. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia 1994;8:382-387.